Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons D. Giesen

Publicaties

89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice

⁸⁹Zr-radiopharmaceuticals to study whole-body distribution and response to antibody-based cancer immunotherapies

Development of 89 Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration

Methods and equipment for quality control of radiopharmaceuticals

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma

Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

(89)ZED88082A PET imaging to visualize CD8(+) T cells in patients with cancer treated with immune checkpoint inhibitor.

First-in-human study of the biodistribution and pharmacokinetics of 89Zr-CX-072, a novel immunopet tracer based on an anti–PD-L1 probody

Moleculaire beeldvorming met 89Zr-immunoPET in translationele studies op het gebied van immuuntherapie

Lees meer